Prosensa will host a webinar on March 25th to provide a status update on their DMD drug drisapersen and follow-on compounds. The webinar, hosted by UPPMD, will feature presentations from Prosensa's CMO and guest speakers from academic medical centers. Patient groups are invited to submit questions in advance. Prosensa also released 48-week data from a US phase II trial of drisapersen and recording of their recent corporate update and financial results are available online.

1.
March
19th
2014
Dear
Patient
Group
Representative,
As
announced
during
Prosensa’s
2013
Earnings
Call
on
March
18th
,
Prosensa
will
present
a
status
update
on
drisapersen
and
its
follow-­‐on
compounds
in
a
patient
focused
webinar
hosted
by
United
Parent
Projects
Muscular
Dystrophy
(UPPMD)
on
Tuesday
25th
of
March
at
1
PM
ET
/
6
PM
CET.
This
webinar
aims
to
keep
the
patient
community
informed
on
the
status
of
Prosensa’s
DMD
programs
and
to
enable
all
patient
organizations
and
their
members
to
submit
questions.
The
webinar
will
be
presented
by
Giles
Campion
MD,
Chief
Medical
Officer
and
Senior
Vice-­‐President
R&D
of
Prosensa
and
he
will
be
joined
by
the
following
guest
speakers:
-­‐ Craig
Campbell
MD
MSc
FRCPC,
Head
of
Section
of
Pediatric
Neurology
at
London
Health
Sciences
Centre,
Associate
Professor
at
Shulich
School
of
Medicine
of
Western
University,
Associate
Scientist
at
Child
Health
Research
Institute
-­‐ Craig
M.
McDonald
MD,
Professor
and
Chair
of
Physical
Medicine
&
Rehabilitation,
Professor
of
Pediatrics
at
University
of
California
Davis
School
of
Medicine
To
Participate:
1.
Visit
www.ReadyTalk.com
and
use
participant
code
9449985.
(Be
sure
to
test
your
computer
beforehand)
2.
Audio
Dial-­‐In
Information:
-­‐
U.S.
&
Canada:
Dial
866.740.1260
and
use
the
Access
Code
9449985
-­‐
Outside
the
U.S.
and
Canada:
Lookup
your
number
(use
code
9449985)
As
you
may
know,
we
issued
a
press
release
on
March
17th
announcing
48-­‐week
data
from
a
U.S.
phase
II
placebo-­‐controlled
study
of
drisapersen
in
51
DMD
boys,
which
is
available
on
our
website
at
http://ir.prosensa.eu/releases.cfm.
Additionally,
Prosensa
provided
Full
Year
2013
Financial
Results
&
a
Corporate
Update
on
March
18th
,
and
the
recording
can
be
accessed
on
our
website
at
http://ir.prosensa.eu/events.cfm.
If
you
have
any
questions
on
these
communications
or
any
other
topic
related
to
our
DMD
portfolio
that
you
would
like
Prosensa
to
address
during
the
webinar,
you
may
submit
these
in
advance
to
UPPMD
at
UPPMD@euronet.nl.
Please
put
‘Prosensa
webinar
question’
in
the
subject
line.
We
will
try
to
answer
as
many
questions
as
possible
during
the
webinar,
and
those
that
we
cannot
address
during
the
call,
will
receive
a
response
at
a
later
time.
For
any
other
questions,
please
do
not
hesitate
to
contact
me.
With
kindest
regards,
Claire
Leyten
Claire
C.M.
Leyten,
PharmD
MBA
Manager
Patient
Group
Relations
E:
patientinfo@prosensa.nl
Prosensa
J.H.
Oortweg
21
,
2333
CH
Leiden,
The
Netherlands
www.prosensa.com